{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:22:09Z","timestamp":1789593729180,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,22]]},"DOI":"10.7759\/cureus.77813","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T11:48:12Z","timestamp":1737546492000},"source":"Crossref","is-referenced-by-count":2,"title":["Monitoring and Management of Uric Acid Therapy in Gout and Chronic Kidney Disease: A Single-Center Retrospective Study"],"prefix":"10.7759","author":[{"given":"Ioannis","family":"Karageorgiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshan","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austen","family":"Grooms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Sardarli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostiantyn","family":"Romaniv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41247","article-title":"2020 American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald JD","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, et al.. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020, 72:879-95. 10.1002\/art.41247","journal-title":"Arthritis Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette P","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, et al.. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017, 76:29-42. 10.1136\/annrheumdis-2016-209707","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna D","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, et al.. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012, 64:1431-46. 10.1002\/acr.21772","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22406","article-title":"Measuring physician adherence with gout quality indicators: a role for natural language processing","volume":"67","author":"Kerr GS","year":"2015","unstructured":"Kerr GS, Richards JS, Nunziato CA, et al.. Measuring physician adherence with gout quality indicators: a role for natural language processing. Arthritis Care Res (Hoboken). 2015, 67:273-9. 10.1002\/acr.22406","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.01.055","article-title":"Management of gout and hyperuricemia in CKD","volume":"70","author":"Vargas-Santos AB","year":"2017","unstructured":"Vargas-Santos AB, Neogi T. Management of gout and hyperuricemia in CKD. Am J Kidney Dis. 2017, 70:422-39. 10.1053\/j.ajkd.2017.01.055","journal-title":"Am J Kidney Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp LK","year":"2011","unstructured":"Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011, 63:412-21. 10.1002\/art.30119","journal-title":"Arthritis Rheum"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1755-0","article-title":"How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose","volume":"20","author":"Stamp LK","year":"2018","unstructured":"Stamp LK, Chapman PT, Barclay ML, et al.. How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. Arthritis Res Ther. 2018, 20:255. 10.1186\/s13075-018-1755-0","journal-title":"Arthritis Res Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00346-9","article-title":"Gout","volume":"388","author":"Dalbeth N","year":"2016","unstructured":"Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016, 388:2039-52. 10.1016\/S0140-6736(16)00346-9","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000861","article-title":"Update on gout management: what is old and what is new","volume":"34","author":"Afinogenova Y","year":"2022","unstructured":"Afinogenova Y, Danve A, Neogi T. Update on gout management: what is old and what is new. Curr Opin Rheumatol. 2022, 34:118-24. 10.1097\/BOR.0000000000000861","journal-title":"Curr Opin Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016679848","article-title":"Monitoring of urate-lowering therapy among US veterans following the 2012 American College of Rheumatology guidelines for management of gout","volume":"51","author":"Hughes JC","year":"2017","unstructured":"Hughes JC, Wallace JL, Bryant CL, Salvig BE, Fourakre TN, Stone WJ. Monitoring of urate-lowering therapy among US veterans following the 2012 American College of Rheumatology guidelines for management of gout. Ann Pharmacother. 2017, 51:301-6. 10.1177\/1060028016679848","journal-title":"Ann Pharmacother"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12799","article-title":"Predicting allopurinol response in patients with gout","volume":"81","author":"Wright DF","year":"2016","unstructured":"Wright DF, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK. Predicting allopurinol response in patients with gout. Br J Clin Pharmacol. 2016, 81:277-89. 10.1111\/bcp.12799","journal-title":"Br J Clin Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22469","article-title":"Gout, urate-lowering therapy, and uric acid levels among adults in the United States","volume":"67","author":"Juraschek SP","year":"2015","unstructured":"Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res (Hoboken). 2015, 67:588-92. 10.1002\/acr.22469","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008","volume":"125","author":"Zhu Y","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012, 125:679-87. 10.1016\/j.amjmed.2011.09.033","journal-title":"Am J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes211","article-title":"Gout and its comorbidities: implications for therapy","volume":"52","author":"Stamp LK","year":"2013","unstructured":"Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology (Oxford). 2013, 52:34-44. 10.1093\/rheumatology\/kes211","journal-title":"Rheumatology (Oxford)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00657-4","article-title":"Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities","volume":"17","author":"Stamp LK","year":"2021","unstructured":"Stamp LK, Farquhar H, Pisaniello HL, et al.. Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities. Nat Rev Rheumatol. 2021, 17:633-41. 10.1038\/s41584-021-00657-4","journal-title":"Nat Rev Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131159","article-title":"Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia","volume":"41","author":"Levy GD","year":"2014","unstructured":"Levy GD, Rashid N, Niu F, Cheetham TC. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. J Rheumatol. 2014, 41:955-62. 10.3899\/jrheum.131159","journal-title":"J Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000679","article-title":"Asymptomatic hyperuricemia: is it really asymptomatic?","volume":"32","author":"Yip K","year":"2020","unstructured":"Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: is it really asymptomatic?. Curr Opin Rheumatol. 2020, 32:71-9. 10.1097\/BOR.0000000000000679","journal-title":"Curr Opin Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.07.021","article-title":"Uric acid as a target of therapy in CKD","volume":"61","author":"Jalal DI","year":"2013","unstructured":"Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013, 61:134-46. 10.1053\/j.ajkd.2012.07.021","journal-title":"Am J Kidney Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura K","year":"2018","unstructured":"Kimura K, Hosoya T, Uchida S, et al.. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018, 72:798-810. 10.1053\/j.ajkd.2018.06.028","journal-title":"Am J Kidney Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/295862-monitoring-and-management-of-uric-acid-therapy-in-gout-and-chronic-kidney-disease-a-single-center-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T11:48:13Z","timestamp":1737546493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/295862-monitoring-and-management-of-uric-acid-therapy-in-gout-and-chronic-kidney-disease-a-single-center-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.77813","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,22]]}}}